Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Financing Activities: 2011-2024

Historic Cash from Financing Activities for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $5.4 million.

  • Niagen Bioscience's Cash from Financing Activities fell 85.76% to $148,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year increase of 595.40%. This contributed to the annual value of $5.4 million for FY2024, which is 6065.56% up from last year.
  • Niagen Bioscience's Cash from Financing Activities amounted to $5.4 million in FY2024, which was up 6,065.56% from -$90,000 recorded in FY2023.
  • In the past 5 years, Niagen Bioscience's Cash from Financing Activities ranged from a high of $36.1 million in FY2021 and a low of -$90,000 during FY2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $5.4 million (2024), whereas its average is $4.3 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 101.18% in 2023, then soared by 6,065.56% in 2024.
  • Niagen Bioscience's Cash from Financing Activities (Yearly) stood at $8.7 million in 2020, then skyrocketed by 317.27% to $36.1 million in 2021, then slumped by 78.79% to $7.7 million in 2022, then tumbled by 101.18% to -$90,000 in 2023, then spiked by 6,065.56% to $5.4 million in 2024.